tiprankstipranks
Trending News
More News >
Addex Therapeutics (ADXN)
NASDAQ:ADXN
US Market

Addex Therapeutics (ADXN) Earnings Dates, Call Summary & Reports

Compare
83 Followers

Earnings Data

Report Date
Mar 05, 2026
TBA (Confirmed)
Period Ending
2025 (Q4)
Consensus EPS Forecast
Last Year’s EPS
-1.68
Same Quarter Last Year
Based on 0 Analysts Ratings

Earnings Call Summary

Q3 2025
Earnings Call Date:Dec 04, 2025|
% Change Since:
|
Earnings Call Sentiment|Neutral
The call highlighted significant progress in key programs and strategic collaborations, which are positive indicators for future growth. However, the need for additional funding for unpartnered programs and stable but limited income suggest challenges in financial sustainability.
Company Guidance
During the Addex Therapeutics Third Quarter 2025 Financial Results and Corporate Update Conference Call, significant guidance was provided. Addex reported progress in their GABAB PAM program, selecting a backup compound and emphasizing their eligibility for up to USD 330 million in milestone payments from their partner, Indivior. They highlighted advancements in their dipraglurant post-stroke recovery program, aiming to address a growing need among over 100 million stroke survivors. Financially, Addex ended Q3 2025 with CHF 2.2 million in cash, ensuring liquidity through mid-2026, although it doesn't cover unpartnered programs. Their investment in Neurosterix, which is progressing with its M4 PAM schizophrenia program, and Stalicla, which is focusing on neurodevelopmental disorders, were also discussed. R&D expenses were CHF 0.2 million, and G&A expenses were CHF 0.5 million for Q3 2025, both stable year-over-year. The call concluded with a Q&A session, during which the commercial outlook for chronic refractory cough, competitive landscape in post-stroke recovery, and potential developments with Indivior were addressed.
Progress in GABAB PAM and Dipraglurant Programs
Addex Therapeutics made excellent progress in their GABAB PAM program for chronic cough and dipraglurant post-stroke recovery. Preclinical characterization and IND-enabling studies have been successfully completed.
Strategic Collaborations and Investments
Addex's partner, Indivior, completed IND-enabling studies for a substance use disorders drug candidate. Addex also invested in Stalicla, which is advancing patient stratification studies in autism and discussions with pharma for broader applications.
Strong Cash Position
The company ended Q3 2025 with CHF 2.2 million in cash, providing a runway through mid-2026. The cash burn has been significantly reduced following the Neurosterix spinout transaction.

Addex Therapeutics (ADXN) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

ADXN Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Mar 05, 2026
2025 (Q4)
- / -
-1.677
Dec 04, 2025
2025 (Q3)
- / -0.01
-2.68599.63% (+2.68)
Sep 30, 2025
2025 (Q2)
- / -1.50
-2.68544.21% (+1.19)
Jun 19, 2025
2025 (Q1)
- / -
-1.345
Apr 25, 2025
2024 (Q4)
- / -2.00
-1.345-48.70% (-0.66)
Nov 22, 2024
2024 (Q3)
- / -
-4.115
Sep 30, 2024
2024 (Q2)
-1.42 / -2.69
-4.11534.75% (+1.43)
Jun 06, 2024
2024 (Q1)
- / -
-5.367
Apr 18, 2024
2023 (Q4)
- / -1.34
-5.36774.94% (+4.02)
Nov 29, 2023
2023 (Q3)
-0.66 / -4.12
11.418-136.04% (-15.53)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

ADXN Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Dec 04, 2025
$8.99$8.38-6.79%
Sep 30, 2025
$9.00$9.46+5.11%
Apr 25, 2025
$7.58$8.16+7.65%
Nov 22, 2024
$8.11$7.53-7.15%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Addex Therapeutics (ADXN) report earnings?
Addex Therapeutics (ADXN) is schdueled to report earning on Mar 05, 2026, TBA (Confirmed).
    What is Addex Therapeutics (ADXN) earnings time?
    Addex Therapeutics (ADXN) earnings time is at Mar 05, 2026, TBA (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is ADXN EPS forecast?
          Currently, no data Available